Blueprint Medicines Corporation 2L9.F Stock
Blueprint Medicines Corporation Price Chart
Blueprint Medicines Corporation 2L9.F Financial and Trading Overview
| Blueprint Medicines Corporation stock price | 84 EUR |
| Previous Close | 53.5 EUR |
| Open | 54.5 EUR |
| Bid | 54.5 EUR x 20000 |
| Ask | 56.5 EUR x 20000 |
| Day's Range | 54.5 - 54.5 EUR |
| 52 Week Range | 35.53 - 75.8 EUR |
| Volume | 200 EUR |
| Avg. Volume | 4 EUR |
| Market Cap | 3.39B EUR |
| Beta (5Y Monthly) | 0.704929 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.8 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 119 EUR |
2L9.F Valuation Measures
| Enterprise Value | 2.65B EUR |
| Trailing P/E | N/A |
| Forward P/E | -8.747993 |
| PEG Ratio (5 yr expected) | 0.16 |
| Price/Sales (ttm) | 16.552479 |
| Price/Book (mrq) | 7.9480824 |
| Enterprise Value/Revenue | 12.968 |
| Enterprise Value/EBITDA | -4.894 |
Trading Information
Blueprint Medicines Corporation Stock Price History
| Beta (5Y Monthly) | 0.704929 |
| 52-Week Change | 21.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 75.8 EUR |
| 52 Week Low | 35.53 EUR |
| 50-Day Moving Average | 47.1 EUR |
| 200-Day Moving Average | 48.58 EUR |
2L9.F Share Statistics
| Avg. Volume (3 month) | 4 EUR |
| Avg. Daily Volume (10-Days) | 20 EUR |
| Shares Outstanding | 60.47M |
| Float | 59.92M |
| Short Ratio | N/A |
| % Held by Insiders | 0.74% |
| % Held by Institutions | 107.34% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -284.018% |
| Operating Margin (ttm) | -271.72% |
| Gross Margin | 88.81% |
| EBITDA Margin | -264.98% |
Management Effectiveness
| Return on Assets (ttm) | -29.39% |
| Return on Equity (ttm) | -89.67% |
Income Statement
| Revenue (ttm) | 204.59M EUR |
| Revenue Per Share (ttm) | 3.42 EUR |
| Quarterly Revenue Growth (yoy) | 0.89% |
| Gross Profit (ttm) | 177.28M EUR |
| EBITDA | -542129984 EUR |
| Net Income Avi to Common (ttm) | -581078016 EUR |
| Diluted EPS (ttm) | -8.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 822.16M EUR |
| Total Cash Per Share (mrq) | 13.6 EUR |
| Total Debt (mrq) | 240.34M EUR |
| Total Debt/Equity (mrq) | 58.01 EUR |
| Current Ratio (mrq) | 5.214 |
| Book Value Per Share (mrq) | 6.857 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -492512000 EUR |
| Levered Free Cash Flow (ttm) | -221860880 EUR |
Profile of Blueprint Medicines Corporation
| Country | Germany |
| State | MA |
| City | Cambridge |
| Address | 45 Sidney Street |
| ZIP | 02139 |
| Phone | 617 374 7580 |
| Website | https://www.blueprintmedicines.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 651 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Q&A For Blueprint Medicines Corporation Stock
What is a current 2L9.F stock price?
Blueprint Medicines Corporation 2L9.F stock price today per share is 84 EUR.
How to purchase Blueprint Medicines Corporation stock?
You can buy 2L9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Blueprint Medicines Corporation?
The stock symbol or ticker of Blueprint Medicines Corporation is 2L9.F.
Which industry does the Blueprint Medicines Corporation company belong to?
The Blueprint Medicines Corporation industry is Biotechnology.
How many shares does Blueprint Medicines Corporation have in circulation?
The max supply of Blueprint Medicines Corporation shares is 61.23M.
What is Blueprint Medicines Corporation Price to Earnings Ratio (PE Ratio)?
Blueprint Medicines Corporation PE Ratio is now.
What was Blueprint Medicines Corporation earnings per share over the trailing 12 months (TTM)?
Blueprint Medicines Corporation EPS is -7.8 EUR over the trailing 12 months.
Which sector does the Blueprint Medicines Corporation company belong to?
The Blueprint Medicines Corporation sector is Healthcare.